Thu, Jan 29, 2015, 8:52 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • sense.mrcommon sense.mrcommon Feb 15, 2013 9:30 PM Flag

    tiger...does your doc know about the monitoring ???????

    .5.8 Hematological Changes
    In clinical trials of at least one year in duration, adverse reactions of decreases in white blood cell count
    (including leukopenia, lymphopenia, neutropenia, and decreased white cell count) were reported in 0.4% of
    patients treated with BELVIQ as compared to 0.2% of patients treated with placebo. Adverse reactions of
    decreases in red blood cell count (including anemia and decreases in hemoglobin and hematocrit) were reported
    by 1.3% of patients treated with BELVIQ as compared to 1.2% treated with placebo [see Adverse Reactions
    (6.1)]. Consider periodic monitoring of complete blood count during treatment with BELVIQ.
    straight from the corporate website - be so advised.............. Less

    SortNewest  |  Oldest  |  Most Replied Expand all replies
4.51-0.050(-1.10%)Jan 29 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million. Inc.
NASDAQThu, Jan 29, 2015 4:00 PM EST
Core Laboratories NV
NYSEThu, Jan 29, 2015 4:00 PM EST